Does daily aspirin prevent first heart attacks in healthy people?
Weak EvidenceNO
Current evidence shows daily aspirin does NOT provide net benefit for primary prevention in healthy people. Modern trials (ASPREE, ARRIVE) demonstrate that bleeding risks outweigh any modest cardiovascular benefit in low-risk populations.
The Verdict
Current evidence shows daily aspirin does NOT provide net benefit for primary prevention in healthy people. Modern trials (ASPREE, ARRIVE) demonstrate that bleeding risks outweigh any modest cardiovascular benefit in low-risk populations.
What the Evidence Shows
The role of aspirin in primary cardiovascular prevention has undergone a dramatic evidence reversal over the past decade. While the 1989 Physicians' Health Study showed a 44% reduction in first myocardial infarction among healthy male physicians taking aspirin, subsequent modern trials in contemporary populations have overturned this recommendation. The 2018 ASPREE trial randomized 19,114 healthy adults over 70 to aspirin or placebo and found no reduction in cardiovascular events but a significant increase in major hemorrhage and higher all-cause mortality (primarily from cancer deaths) in the aspirin group. The ARRIVE trial, enrolling 12,546 moderate-risk patients, similarly showed no significant reduction in cardiovascular events with aspirin but doubled gastrointestinal bleeding risk. The Antithrombotic Trialists' meta-analysis had previously shown that aspirin reduces serious vascular events by about 12% in primary prevention, but this modest benefit is offset by a comparable increase in major bleeding. The shift in evidence likely reflects improved background cardiovascular risk management (widespread statin use, better hypertension control, smoking decline) that reduces the absolute benefit of adding aspirin. Current guidelines from the USPSTF, AHA, and ESC no longer recommend routine aspirin for primary prevention in most adults.
Evidence Quality
1
Meta-Analyses
6
RCTs
2
Observational
Important Caveats
- ⚠️ Aspirin remains clearly beneficial for secondary prevention (after a heart attack or stroke)
- ⚠️ A small subgroup aged 40-59 with high 10-year cardiovascular risk (>10%) and low bleeding risk may still benefit
- ⚠️ Earlier trials showing benefit were conducted in eras with less background cardiovascular risk management
- ⚠️ Individual risk-benefit calculation should guide decisions rather than blanket recommendations
- ⚠️ The low confidence score reflects that evidence now shows NO benefit for the primary prevention question asked
Population Studied
Healthy adults without prior cardiovascular disease; ASPREE enrolled 19,114 adults ≥70 years; ARRIVE enrolled 12,546 adults with moderate risk; Physicians' Health Study enrolled 22,071 male physicians
Dosage
Low-dose aspirin 75-100 mg daily in most modern trials; 325 mg every other day in Physicians' Health Study
Duration
ASPREE median 4.7 years; ARRIVE median 5 years; Physicians' Health Study 5 years; Antithrombotic Trialists' meta-analysis trials ranged 3-10 years
Supporting Studies (3)
Final report on the aspirin component of the ongoing Physicians' Health Study
RCTSteering Committee of the Physicians' Health Study Research Group. · New England Journal of Medicine (1989)
In 22,071 healthy male physicians, aspirin 325 mg every other day reduced first myocardial infarction by 44% over 5 years, establishing the historical basis for primary prevention aspirin use.
View paper (DOI) →Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
Meta-AnalysisAntithrombotic Trialists' (ATT) Collaboration. · Lancet (2009)
Individual participant meta-analysis of 6 primary prevention trials (95,000 participants) found aspirin reduces serious vascular events by 12% but increases major bleeding proportionally, resulting in uncertain net benefit for low-risk individuals.
View paper (DOI) →Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE)
RCTGaziano JM, Brotons C, Coppolecchia R, et al. · Lancet (2018)
In 12,546 patients at moderate cardiovascular risk, aspirin 100 mg daily did not significantly reduce the primary composite cardiovascular endpoint but doubled gastrointestinal bleeding events compared to placebo.
View paper (DOI) →Contradicting Studies (1)
Effect of Aspirin on Disability-free Survival in the Healthy Elderly (ASPREE)
RCTMcNeil JJ, Wolfe R, Woods RL, et al. · New England Journal of Medicine (2018)
In 19,114 healthy adults ≥70 years, aspirin 100 mg daily did not reduce cardiovascular events or prolong disability-free survival but significantly increased major hemorrhage and was associated with higher all-cause mortality compared to placebo.
Why this disagrees:
Provides definitive evidence that in contemporary healthy elderly populations with well-managed cardiovascular risk factors, aspirin provides no cardiovascular benefit while substantially increasing bleeding risk and potentially increasing cancer mortality, completely reversing the historical primary prevention recommendation.
Related Claims
Does high blood pressure increase stroke risk?
Strong EvidenceOverwhelming evidence from prospective studies involving over 1 million participants and meta-analyses of treatment trials establishes hypertension as the single strongest modifiable risk factor for stroke, with a continuous dose-response relationship.
Does the Mediterranean diet reduce cardiovascular risk?
Strong EvidenceStrong evidence from large RCTs and meta-analyses shows the Mediterranean diet significantly reduces cardiovascular events, including heart attacks and strokes, by approximately 30% compared to control diets.
Do statins reduce heart attack risk?
Strong EvidenceVery strong evidence from large meta-analyses of randomized trials demonstrates that statins reduce major cardiovascular events by approximately 20-25% per 1 mmol/L reduction in LDL cholesterol, with consistent benefits across diverse populations.